Introduction
Following vascular injury, the adhesion of platelets to the exposed subendothelial extracellular matrix together with platelet aggregation are essential steps in primary haemostasis. Subsequent fibrin formation not only stabilizes the temporary thrombus but also seals the platelet plug against diffusion of platelet secretory products, such as clotting factors, cell stimulatory agonists or regulatory growth factors (1) . At high shear rates platelets predominantly stick to von Willebrand factor and collagen, whereas under low shear rate or static conditions several other extracellular matrix proteins, such as fibrin and vitronectin (VN) mediate αIIbß3-integrin-dependent platelet adhesion via their Arg-Gly-Asp (RGD) sequence. Furthermore, binding of different agonists, such as adenosine-diphosphate (ADP), thrombin or collagen induces signalling events ultimatively activating the receptor function of αIIbß3-integrin for soluble fibrinogen leading to platelet aggregation (2-6).
Due to its distribution between the flowing blood and the underlying tissues, VN is believed to exhibit several regulatory functions, particularly during vascular remodelling (7, 8) .
The multimeric form of VN becomes incorporated into the vascular extracellular matrix (9, 10) , accumulates in fibrotic and necrotic deposits of atherosclerotic vessels (11) , and via its interaction with αIIbß3-and αv-integrins, VN can regulate adhesion and migration of vascular cells. Furthermore, multimeric forms of VN are secreted together with plasminogen activator inhibitor-1 (PAI-1) during platelet activation/ aggregation (12, 13) and provide a basis for stabilizing thrombus formation by concentrating PAI-1 at these fibrin-rich sites to prevent early formation of plasmin (14) . Previous reports on the role of VN in platelet aggregation were contradictory, since it has been reported that exogenous VN as well as inhibitory antibodies against VN inhibit platelet aggregation (15) (16) (17) .
HK and especially HKa were previously reported to exert anti-adhesive properties (18) .
Initially identified as a non-enzymatic cofactor in the initiation of the contact phase (19, 20) , HK appears to be associated with vascular injury, inflammation or activation of complement in was kindly provided by Dr. P. Declerck (Leuven, Belgium) (12, 40) and polyclonal rabbit-anti-FBG was from DAKO (Hamburg, Germany). ZnCl 2 and ADP were from Sigma (Munich, Germany). Peroxidase-conjugated streptavidin as well as secondary anti-mouse and anti-rabbit immunoglobulins were from DAKO (Hamburg, Germany).
Isolation of platelets. Blood was collected with polypropylene syringes into 3.8% trisodium citrate, pH 6.4, reaching a final concentration of 0.38%. Platelet-rich plasma was obtained by centrifugation at 150 g for 20 min at 22°C. Platelets were pelleted by centrifugation at 400 g for 5 min at 22°C, washed and resuspended in HEPES-Tyrode buffer (138 mM NaCl, 2.9 mM KCl, 1 mM MgCl 2 , 5 mM glucose, 3.5% (w/v) BSA, 33 mM NaH 2 PO 4 , 20 mM HEPES, pH 6.4). After counting, platelets were diluted with HEPES-Tyrode buffer to 1x10 8 platelets/ml.
Cell culture. Human megakaryoblastic cell lines CHRF-288 (kindly provided by Dr. B.
Lieberman, Cincinnati, Ohio) and MEG-01 (obtained from DSM, Braunschweig, Germany), were maintained in suspension culture with 10% (v/v) fetal calf serum as described (41) . Addition of 10 ng/ml PMA induced cellular differentiation along the megakaryoblastic lineage. The cell lines were found to be free from mycoplasma contamination using a mycoplasma detection kit (Stratagene, La Jolla, CA).
In vitro binding assay. Maxisorp plates (high binding capacity; Nunc) were coated with 5 µg/ml αIIbß3 integrin in TBS, pH 7. Platelet adhesion assay. Platelet adhesion onto VN-, or FBG-coated plates (and to BSA-coated wells as control) was tested according to a previously described protocol (42) . Briefly, multiwell
plates were coated for 16 h at 4°C with 5 µg/ml multimeric VN or 10 µg/ml FBG (dissolved in bicarbonate buffer, pH 9.6), respectively, and then blocked with 3% (w/v) BSA. Platelets stained with calcein acetoxymethyl ester (calcein-AM, 2.5 µM) (Molecular Probes Europe BV, Leiden,
The Netherlands) (15 min at 37°C in the dark) at a density of 5x10 6 Statistics. Data were compared using ANOVA and the Student´s t test; P values <0.05 were considered as significant.
Results

The region G486-K502 of domain 5 mediates the binding of kininogen to VN.
We have previously demonstrated that multimeric VN interacts with HKa and to a much lesser extent with HK in a Zn
2+
-dependent manner; moreover, VN binding was attributed to domain 5 of HK (34) . Here, peptides derived from this domain were used to further identify the responsible epitope on HKa for interaction with multimeric VN. Multimeric VN only interacted with the carboxy-terminal region of the domain 5, H475-K502 fused to GST, whereas no binding to the amino-terminal portion of domain 5, K420-D474 fused to GST, was observed (Fig. 1A) . (H475-H485) had no effect (Fig. 1B) . The sequence specificity of the peptides HK486 and HK483 containing a high proportion of Gly, His, Lys was proven by the fact that the respective scrambled peptides, HK486M and HK483M, hardly inhibited the binding of multimeric VN to HKa (Fig. 1B) . The inhibition of the interaction between multimeric VN and HKa by the different peptides derived from domain 5 was markedly augmented in the presence of zinc ions, whereby the minimal concentration of free Zn2+ required was 10 µM. These data demonstrate that the sequence G486-K502 of domain 5 is responsible for the Zn 2+ -dependent binding of HKa to multimeric VN.
Inhibition of the αIIbß3-VN-interaction by the region G486-K502 of HK.
Immobilized multimeric VN serves as a ligand for αv-and αIIbß3-integrins, and we previously showed that HKa binding to the amino-terminal "somatomedin B" domain of VN competes for αvß3-integrin binding, thereby resembling the activity of PAI-1 as an anti-adhesive component (34) . Binding of both multimeric VN and FBG to immobilized αIIbß3-integrin was inhibited by the αIIbß3-inhibitor KC13972 but not by the αvß3-inhibitor cyclic RGDfV-peptide. HKa but not HK could compete for the binding of only VN but not of FBG to αIIbß3 in a Zn 2+ -dependent manner, an effect that was reminiscent of the activity of PAI-1 and of the inhibitory monoclonal antibody 13H1 against multimeric VN ( Fig. 2A) . Again, domain 5 but not domains 3 or 6 of HK was responsible for inhibiting the αIIbß3-VN interaction (Table 1 and Fig. 2B ). The IC50 of HKa or domain 5 in this respect (< 100 nM for both forms) was about 5 times higher as compared to the IC50 of PAI-1 in the same reaction (about 20 nM) (Fig. 2B ). Using different polypeptides derived from domain 5, the inhibitory activity of HKa on the αIIbß3-VN interaction could be localized within the same region of the carboxy-terminus of domain 5 that also mediated binding to VN (Table 1) : Binding of multimeric VN to αIIbß3-integrin was blocked by the peptide HK486 (and to a lower extent by HK483), whereas the respective scrambled peptides exhibited reduced potency, and domain 5 peptides HK406, HK440 or HK475 had no effect. Taken together, these data underline our observations that the sequence G486-K502 of domain 5 can directly interfere with the αIIbß3-VN interaction in a purified system.
Inhibition of platelet adhesion by HKa.
As previously established, adhesion of platelets to VN and FBG is mediated by the αIIbß3-integrin, whereas cell lines of the megakaryoblastic lineage, such as CHRF-288 or MEG-01, engage αvß3-integrin for adhesion to VN, although they express both αIIbß3-and αvß3-integrins after stimulation with PMA (41) . In agreement with the inhibition of the αIIbß3-VN interaction in a purified system, HKa and particularly the isolated domain 5 could block the αIIbß3-mediated adhesion of platelets to VN but not to FBG (Fig. 3) . Again, adhesion to VN was blocked by (Fig. 4A) . Moreover, only peptides HK486 (and HK483 to a lower extent) competed with platelet adhesion to VN (Fig. 4B) , indicating that the sequence G486-K502 of domain 5 can directly block the αIIbß3-dependent adhesion of platelets to VN.
Inhibition of platelet aggregation by the region G486-K502 of HK.
The role of VN in platelet aggregation is still unclear; exogenously added VN has been reported to block platelet aggregation, probably by competing with other αIIbß3-integrin ligands (15,16), whereas antibodies against VN also decrease platelet aggregation (17) . These partially conflicting data point to a potential role of platelet-derived multimeric VN, which becomes released from platelets upon degranulation (12, 13) . By examining the role of domain 5-derived peptides on platelet aggregation we have approached to solve this controversy. The monoclonal antibody 13H1 against multimeric VN, which inhibits binding of VN to integrins (see Fig. 2A ), could markedly reduce ADP-induced platelet aggregation (Fig. 5A ). In contrast, other monoclonal antibodies, which recognize both the native and multimeric form of the protein had no effect (Fig.   5A , only data with monoclonal antibody VN7 are shown). In addition, the inhibitory effect of antibody 13H1 on platelet aggregation was reversed in the presence of multimeric but not of native VN. Interestingly, addition of exogenous multimeric VN but not native VN had also a lower but significant inhibitory activity on ADP-induced platelet aggregation (Fig. 5A ). Taken 5-derived peptides on platelet aggregation was analyzed. Both, domain 5 and the peptide HK486 markedly reduced ADP-induced platelet aggregation, and this inhibitory activity was reversible in the presence of multimeric but not of native VN. In contrast, the scrambled peptide HK486M
was not effective (Fig. 5B) . Apart from peptide HK483 that also decreased platelet aggregation to a lower extent, peptides HK406, HK440 or HK475 did not exert an inhibitory activity on platelet aggregation (data not shown). The IC50 of domain 5 and HK486 was approximately 2 and 3.5 µM, respectively ( 
Localization and colocalization of HK/HKa and VN in resting platelets
The control labelings without the primary antibodies were negative in each of the following localization experiments. The localization of HKa in resting human platelets was carried out with sheep antibodies against HK (As94). The localization of VN was determined with a polyclonal rabbit antibody (S66/67) against VN. The distribution of VN on the platelet surface, on the membranes of the surface-connected membrane system and within α-granules was demonstrated elsewhere (41, 46) . As shown in Fig. 7a , HK/HKa was present on the platelet surface, on the membranes of the surface-connected membrane system and within α-granules.
After double labeling, the density of labels was lower than after use of single primary
antibodies. This may be due to steric hindrance of the molecules involved in antibody-antigen interaction. On the other hand, the specificity of colocalized label was very high. As shown in the surface-connected membrane system (Fig. 7c) and within α-granules (Fig. 7d) .
Localization and colocalization of HK/HKa and VN in platelet-rich fibrin clots.
Under the condition of our experiments using kaolin/phospholipid reagent to induce clot formation, fibrin fibers adhering to the surface of activated, degranulating platelets were observed. Using monoclonal antibodies against the multimeric form of VN, its distribution in clots, was shown elsewhere (46) . HK/HKa was present on the platelet surface, on polymerizing fibrin within the degranulating α-granules and on fibrin fibers (Fig.8a) . As shown in Fig. 8b , HK/HKa was also localized on the polymerizing fibrin associated with the membranes of the degranulating α-granules that form compound granules (46, 47) . After double labeling, the density of labels was low, however, the specificity of colocalized labels was very high. Colocalizations of VN and HK/HKa were also observed on the platelet surface and within compound granules (Fig.   8b ). As shown in Fig. 8c 
Discussion
Apart from its role as precursor of bradykinin, which serves important vasodilator functions in vascular homeostasis, high molecular weight kininogen exhibits anti-adhesive and antithrombotic properties, especially in the two chain, kinin-free form (HKa) (18, (32) (33) (34) (35) 48) . In the present study we continued to define the underlying mechanisms of these functions of HKa, related to disruption of αIIbß3-mediated platelet adhesion and aggregation. Considerable quantities of HK/HKa are found associated with the surface of platelets or within the platelet releasate (49, 50) .
Also ultrastructurally, HK/HKa is present already during platelet degranulation at sites of fibrin polymerization and appears to be colocalized with VN (see Fig. 8 ) (46) . Indeed, at sites of thrombus formation, colocalization of VN and HK/HKa in platelet-rich clots was observed by electron microscopy both in proximity to the platelet surface, to polymerizing fibrin on the luminal surface of degranulating α-granules and on fibrin fibers. Together, these observations define HKa and fragments thereof as important regulators of platelet function, since they can interfere with ligand binding to αIIbß3-integrin. Indeed, these antithrombotic properties of HK were corroborated in HK-deficient rats, which were presented with a prothrombotic phenotype upon arterial injury (48) , whereas VN seems to promote vascular thrombosis in vivo (53, 54) .
Besides the inhibitory properties of HK for VN-dependent platelet adhesion and aggregation described in the present study, previous reports have demonstrated that HK can bind to thrombospondin and to glycoprotein Ib-IX-V complex on platelets (30, 31) . The latter interaction, attributable to domain 3 of HK, mediates one of the two pathways for inhibition of thrombin-dependent platelet aggregation by HK, a property that has also been ascribed to breakdown products of bradykinin (32, 33) . In addition to interactions of extracellular HK with platelets, α-granule-derived HK can also inhibit the function of platelet calpain, an effect mainly mediated by domain 2 of HK (55) . Calpain is selectively activated at sites of ligand-occupied αIIbß3-integrin and can cleave proteins present in integrin signaling complexes, thereby playing an important role in mediating integrin-induced signaling and retraction of platelet-rich thrombi (56) .
Overlapping with the region of HK detected here as the major VN binding site (H483-K502) is the HK sequence (H475-G497) that was identified as the major binding site for the ß2-integrin Mac-1 on leukocytes (35) and the sequence (K480-T503), which was recently described to induce endothelial cell apoptosis, to inhibit endothelial cell migration or angiogenesis (38, 57) . 
